Dr. Rizvi on the Utility of Trastuzumab Deruxtecan in NSCLC
Note: this is in context of HER2, another resistance mechanism of EGFR TKIs.
Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi.
According to data from the phase 2 DESTINY-Lung01 trial, trastuzumab deruxtecan induced a confirmed objective response rate of 61.9%, including a 2.4% complete response rate, a 59.5% partial response rate, and a 28.6% stable disease rate.
Future research should explore this agent in the first-line setting as a single agent and a combination therapy, Rizvi concludes. Read more.